Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Active not recruiting 3Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 2Gastric and Gastroesophageal Junction Adenocarcinoma 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × tipiracil × Clear all
NCT07491159 2026-03-24

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2 Active not recruiting
106 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Yonsei University

Phase 1/2 Active not recruiting
75 enrolled
Gastrointestinal

Gastric and Gastroesophageal Junction Adenocarcinoma

NCT05201352 2025-05-30

TASKIN

Centre Georges Francois Leclerc

Phase 1/2 Active not recruiting
160 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡